Medical groups launch diabetes registry

Four organizations are joining forces to launch the first ever diabetes registry that is aimed at tracking and improving the quality of diabetes and cardiometabolic care across the primary and specialty care continuum.

The Diabetes Collaborative Registry, launched by the American College of Cardiology (ACC), the American Diabetes Association, the American College of Physicians and Joslin Diabetes Center, will allow for a longitudinal study of diabetes presentation, progression, management and outcomes as patients receive treatment from multidisciplinary care teams, according to a release from ACC.

This registry will leverage data on patients with diabetes in the ACC’s PINNACLE Registry, an established platform that receives data from EMRs collected by participating primary care physicians, endocrinologists, cardiologists and other diabetes care providers. Through the registry, physicians will be able to track adherence to performance measures at the provider and practice level, compare performance to national benchmarks and target quality improvement areas, according to ACC.

“Cardiovascular disease is the leading cause of death among people with diabetes, and there is a clear need for cross-specialty management of diabetes patients. By consolidating patient data, this registry will allow primary care physicians and specialists who treat patients with diabetes to compare data and access real-time metrics on patients in all stages of the disease,” said ACC President Patrick T. O’Gara, MD, in a statement.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.